ASCO President-Elect Julie Vose, MD, MBA

2015 ASCO Annual Meeting

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, reflects on the 2015 Annual Meeting and her year ahead as ASCO President.

Thomas W. LeBlanc, MD, and Eric Roeland, MD, FAAHPM, on Palliative Care for Patients With Hematologic Malignancies

Thomas W. LeBlanc, MD, of Duke University Medical Center, and Eric Roeland, MD, FAAHPM, of the University of California, San Diego Moores Cancer Center, discuss the use of palliative and hospice care for patients with solid tumors vs hematologic cancers and clinicians’ attitudes (Abstracts e20554 and 9524).

Skin Cancer

Jedd Wolchok, MD, PhD

Jedd Wolchok, MD, PhD, Summarizes Results From the CheckMate 067 Trial in Advanced Melanoma

Jedd Wolchok, MD, PhD, of Memorial Sloan Kettering Cancer Center discusses therapies for treatment-naive patients with advanced melanoma (Abstract LBA1).

Global Cancer Care

Gynecologic Cancers

Eduardo Cazap, MD, PhD and James O. Armitage, MD

Eduardo Cazap, MD, PhD, and James O. Armitage, MD, on The Current State of Cancer Research and Treatment: The Latin American Perspective

Eduardo Cazap, MD, PhD, of the Latin American & Caribbean Society of Medical Oncology, and James O. Armitage, MD, of the University of Nebraska Medical Center, discuss oncology from an international point of view.

Skin Cancer

Andrew James Martin, PhD

Andrew James Martin, PhD, on Oral Nicotinamide for Nonmelanoma Skin Cancer

Andrew James Martin, PhD, of NHMRC Clinical Trials Centre, University of Sydney, discusses a form of vitamin B3 that reduced the incidence of new nonmelanoma skin cancers in high-risk patients (Abstract 9000).

Colorectal Cancer

Chloe Evelyn Atreya, MD, PhD, and Axel Grothey, MD

Chloe Evelyn Atreya, MD, PhD, and Axel Grothey, MD, on Efficacy of Targeted Treatments in BRAF-Mutated Metastatic Colorectal Cancer

Chloe Evelyn Atreya, MD, PhD, of the University of California, San Francisco, talks with Axel Grothey, MD, of the Mayo Clinic, about new data on trametinib, dabrafenib, and panitumumab in patients with the BRAF V600E mutation and vemurafenib plus irinotecan and cetuximab in BRAF-mutated metastatic colorectal cancer (Abstracts 103 and 3511).

Jun

Today In Oncology

ASCO President-Elect Julie Vose, MD, MBA

Related Videos

Thomas W. LeBlanc, MD, and Eric Roeland, MD, FAAHPM, on Palliative Care for Patients With Hematologic Malignancies

Jedd Wolchok, MD, PhD, Summarizes Results From the CheckMate 067 Trial in Advanced Melanoma

Eduardo Cazap, MD, PhD, and James O. Armitage, MD, on The Current State of Cancer Research and Treatment: The Latin American Perspective

Andrew James Martin, PhD, on Oral Nicotinamide for Nonmelanoma Skin Cancer

Chloe Evelyn Atreya, MD, PhD, and Axel Grothey, MD, on Efficacy of Targeted Treatments in BRAF-Mutated Metastatic Colorectal Cancer

Neoadjuvant Sacituzumab Govitecan in MIBC

Thyroid Cancer Reproductive Lifespan, Hormone Therapy Potentially Linked to Incidence

Two-Pronged Nudges Result in Timely Conversations Around Priorities of Cancer Care

MIBC Intravesical Recombinant BCG and Chemoimmunotherapy

Overall Survival Benefit With Ivonescimab Plus Chemotherapy in Advanced Squamous NSCLC